

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) An antibody against protein C or activated protein C (aPC), comprising the ~~activity of potentiating an activity of activated protein C in vivo~~heavy chain complementarity determining regions (CDRs) 1, 2, and 3 having the sequences of SEQ ID NOs: 9, 10, and 11, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 21, 22, and 23, respectively.

2-6. (Canceled)

7. (Currently amended) The antibody of claim 1, wherein the antibody is selected from the group consisting of a ~~human antibody, humanized antibody,~~ chimeric antibody, antibody fragment, single-chain antibody, and diabody.

8. (Currently amended) A composition comprising the antibody of claim 1[[,]] and a pharmaceutically acceptable carrier.

9-15. (Canceled)

16. (New) The antibody of claim 1, wherein the antibody is a human antibody or a humanized antibody.

17. (New) An antibody that binds to the same epitope of protein C or aPC as an antibody comprising the CDR sequences of any of one of:

(a) the heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 9, 10, and 11, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 21, 22, and 23, respectively;

(b) heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 31, 32, and 33, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 24, 25 and, 34, respectively; or

(c) heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 15, 16, and 17, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 27, 28, and 29, respectively.

18. (New) The antibody of claim 17, wherein the antibody is selected from the group consisting of a human antibody, humanized antibody, chimeric antibody, antibody fragment, single-chain antibody, and diabody.

19. (New) A composition comprising the antibody of claim 17 and a pharmaceutically acceptable carrier.

20. (New) An antibody against protein C or aPC comprising heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 31, 32, and 33, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 24, 25 and, 34, respectively.

21. (New) The antibody of claim 20, wherein the antibody is a human antibody or a humanized antibody.

22. (New) The antibody of claim 20, wherein the antibody is selected from the group consisting of a chimeric antibody, antibody fragment, single-chain antibody, and diabody.

23. (New) A composition comprising the antibody of claim 20 and a pharmaceutically acceptable carrier.

24. (New) An antibody against protein C or aPC comprising heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 15, 16, and 17, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 27, 28, and 29, respectively.

25. (New) The antibody of claim 24, wherein the antibody is a human antibody or a humanized antibody.

26. (New) The antibody of claim 24, wherein the antibody is selected from the group consisting of a chimeric antibody, antibody fragment, single-chain antibody, and diabody.

27. (New) A composition comprising the antibody of claim 24 and a pharmaceutically acceptable carrier.